SAB Biotherapeutics
Price & Volume
Stats
See moreOpen | $2.86 |
Previous Close | $2.97 |
Day Range | $2.86-$3 |
52W Range | $2.16-$9.72 |
Market Cap | $27.4M |
Shares Short | 58,763 |
Financials
See moreRevenue (12 Mos) | $1.5M |
Revenue Growth (YoY) | 207.7% |
Gross Profit (12 Mos) | -$12.5M |
Diluted EPS | -$6.30 |
News
See moreYahoo Finance • 12 months ago
SAB Biotherapeutics Announces Commencement of the HUMAN Phase 1 Clinical Trial with SAB-142, a Potential Disease-Modifying Treatment for Type 1 Diabetes
Yahoo Finance • last year
SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors
Yahoo Finance • last year
SAB Biotherapeutics Announces Completion of $67.1 Million Financing to Advance Potential Disease-Modifying Treatment for Type 1 Diabetes
Yahoo Finance • last year
SAB Biotherapeutics Announces Q3 2023 Financial Results and Provides Company Updates
About
CEO | Mr. Samuel J. Reich |
Address | 777 W 41st St., Miami Beach, FL, United States, 33140 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 57 |
